IOVANCE BIOTHERAPEUTICS, INC. Operating Leases, Rent Expense
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Operating Leases, Rent Expense of $1.00 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LeaseAndRentalExpense · last filed 2019-02-28
- IOVANCE BIOTHERAPEUTICS, INC. operating leases, rent expense for the quarter ending 2018-12-31 was $300.00K, a 0.00% change year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. operating leases, rent expense for the quarter ending 2018-09-30 was $200.00K, a 33.33% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. operating leases, rent expense for the quarter ending 2018-06-30 was $200.00K, a 0.00% change year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. operating leases, rent expense for the quarter ending 2018-03-31 was $300.00K, a 50.00% increase year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. operating leases, rent expense for fiscal 2018 was $1.00M, a 0.00% change from fiscal 2017.
- IOVANCE BIOTHERAPEUTICS, INC. operating leases, rent expense for fiscal 2017 was $1.00M, a 42.86% increase from fiscal 2016.
- IOVANCE BIOTHERAPEUTICS, INC. operating leases, rent expense for fiscal 2016 was $700.00K, a 133.33% increase from fiscal 2015.
- IOVANCE BIOTHERAPEUTICS, INC. operating leases, rent expense for fiscal 2015 was $300.00K, a 200.00% increase from fiscal 2014.
| Period end | Operating Leases, Rent Expense 1 month | Operating Leases, Rent Expense 3 month | Operating Leases, Rent Expense 6 month | Operating Leases, Rent Expense 9 month | Operating Leases, Rent Expense 12 month |
|---|---|---|---|---|---|
| 2018-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $500.00K derived: sum of 2 quarters · filed 2019-02-28 | $700.00K derived: sum of 3 quarters · filed 2019-02-28 | $1.00M 10-K · filed 2019-02-28 | |
| 2018-09-30 | $200.00K 10-Q · filed 2018-11-06 | $400.00K derived: sum of 2 quarters · filed 2018-11-06 | $700.00K 10-Q · filed 2018-11-06 | $1.00M derived: sum of 4 quarters · filed 2019-02-28 | |
| 2018-06-30 | $200.00K 10-Q · filed 2018-08-07 | $500.00K 10-Q · filed 2018-08-07 | $800.00K derived: sum of 3 quarters · filed 2019-02-28 | $1.10M derived: sum of 4 quarters · filed 2019-02-28 | |
| 2018-04-20 | $7.00K 10-Q · filed 2018-08-07 | ||||
| 2018-03-31 | $300.00K 10-Q · filed 2018-05-10 | $600.00K derived: sum of 2 quarters · filed 2019-02-28 | $900.00K derived: sum of 3 quarters · filed 2019-02-28 | $1.10M derived: sum of 4 quarters · filed 2019-02-28 | |
| 2017-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $600.00K derived: sum of 2 quarters · filed 2019-02-28 | $800.00K derived: sum of 3 quarters · filed 2019-02-28 | $1.00M 10-K · filed 2019-02-28 | |
| 2017-09-30 | $300.00K 10-Q · filed 2018-11-06 | $500.00K derived: sum of 2 quarters · filed 2018-11-06 | $700.00K 10-Q · filed 2018-11-06 | $1.00M derived: sum of 4 quarters · filed 2019-02-28 | |
| 2017-06-30 | $200.00K 10-Q · filed 2018-08-07 | $500.00K 10-Q · filed 2018-08-07 | $700.00K derived: sum of 3 quarters · filed 2019-02-28 | $900.00K derived: sum of 4 quarters · filed 2019-02-28 | |
| 2017-03-31 | $200.00K 10-Q · filed 2018-05-10 | $500.00K derived: sum of 2 quarters · filed 2019-02-28 | $700.00K derived: sum of 3 quarters · filed 2019-02-28 | $800.00K derived: sum of 4 quarters · filed 2019-02-28 | |
| 2016-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $500.00K derived: sum of 2 quarters · filed 2019-02-28 | $600.00K derived: sum of 3 quarters · filed 2019-02-28 | $700.00K 10-K · filed 2019-02-28 | |
| 2016-09-30 | $200.00K 10-Q · filed 2017-11-02 | $300.00K derived: sum of 2 quarters · filed 2017-11-02 | $400.00K 10-Q · filed 2017-11-02 | ||
| 2016-06-30 | $100.00K 10-Q · filed 2017-08-03 | $200.00K 10-Q · filed 2017-08-03 | |||
| 2016-03-31 | $100.00K 10-Q · filed 2017-05-03 | ||||
| 2015-12-31 | $300.00K 10-K · filed 2018-03-12 | ||||
| 2014-12-31 | $100.00K 10-K · filed 2017-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |